|
Comments
Did you read today's front page stories & breaking news?
SYS-CON.TV
|
From the Wires
Excellent Stem Cell Mobilization and Safety Profile for TG-0054
By: PR Newswire
Sep. 28, 2009 06:20 AM
The trial was a randomized, double-blind, placebo-controlled, single intravenous dose study including 64 healthy volunteers in US, to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of TG-0054 in 8 cohorts. The mobilized stem and progenitor cells peaked at 4-6 hours following one single intravenous dose. "We are greatly encouraged by the phase 1 study results which indicates
that TG-0054 has the potential to be used alone, not in combination with G-
CSF, for allogenic or autologous stem cell transplantation in cancer patients.
This should greatly reduce the hospital and other associated cost for such a
procedure. Importantly, the activity and safety profile in the phase 1 study
will support our future development of TG-0054 in chemosensitization and
tissue ischemia, including myocardial infarction, stroke and severe
intermittent claudication. Our preclinical animal disease models and the phase
1 study results lend strong support to clinical development for these clinical
indications," said Dr. About TaiGen Biotechnology TaiGen Biotechnology ( http://www.taigenbiotech.com/ ) is a leading
development stage pharmaceutical company based in
TaiGen Contact
Dr. Stephen Ip, Sr. VP Global Business Development
Tel: +886-2-2790-1861
Email: Stephenip@taigenbiotech.com.tw
SOURCE TaiGen Biotechnology Co., Ltd. Latest Cloud Developer Stories
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
|
SYS-CON Featured Whitepapers
Most Read This Week
Breaking Cloud Computing News
|
|||||||||||||||||||||||||||||||||||||||||||||||||